Bayer Doubles OTC Presence In China With Dihon Acquisition
This article was originally published in PharmAsia News
Executive Summary
Bayer AG acquired its second Chinese over-the-counter company to scale up amid the country’s OTC consolidation trend.
You may also be interested in...
Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.